Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07YRW
|
|||
| Former ID |
DNCL003346
|
|||
| Drug Name |
ASP7991
|
|||
| Indication | Hyperparathyroidism [ICD-11: 5A51; ICD-9: 252.02, 588.81] | Phase 2 | [1] | |
| Company |
Astellas
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular calcium-sensing receptor (CASR) | Target Info | Agonist | [2] |
| Pathway Interaction Database | E-cadherin signaling in keratinocytes | |||
| Reactome | G alpha (q) signalling events | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02133404) A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.